ATR, short for ataxia-telangiectasia and Rad3-related, belongs to the PIKK family of giant kinases that also includes ATM, DNA-PKcs, mTOR and SMG1. Like its siblings, ATR is an enormous HEAT-repeat scaffold carrying a kinase domain buried deep within, and it operates as a dimer paired with its obligate partner ATRIP. Since the first cryo-EM structures of human ATR–ATRIP appeared in 2018, researchers have known the complex’s overall architecture but not the physical choreography of its activation. The central puzzle has been phosphorylation: ATR autophosphorylates itself, and this modification is considered a hallmark of the active kinase, yet nobody had seen structurally what phosphorylation does to the machine or how the activator protein TopBP1 drives the process. The new study addresses that gap directly by trapping the complex at successive stages of its catalytic cycle.

The team began with precatalytic snapshots. In two structures determined with the non-hydrolysable ATP analogue ATPγS wedged in the active site, they found that nucleotide binding alone accomplishes something remarkable: it primes the catalytic center for chemistry without wholesale rearrangement of the kinase domain. When the researchers then added a fragment of Chk1, the key downstream effector of the ATR pathway, the substrate docked neatly onto the primed enzyme. In other words, ATP binding and substrate positioning can proceed as relatively independent, modest steps rather than requiring a dramatic conformational detonation. This finding revises the textbook expectation that PIKK kinases need massive global movements to become catalytically competent, and it suggests that the rate-limiting event in ATR activation lies elsewhere — specifically, in the regulatory rearrangements triggered by TopBP1.

That TopBP1-dependent rearrangement is the structural centerpiece of the paper. In the activated structure, two molecules of TopBP1 bind simultaneously to the ATR–ATRIP dimer, one engaging each protomer from opposite faces. TopBP1 latches onto the HEAT-repeat scaffold far from the active site, and in doing so it locks the N-HEAT and M-HEAT domains of ATR together in both protomers. In the precatalytic and substrate-bound states, these scaffold elements make intimate contact in one protomer while hovering apart in the other — an inherent asymmetry. TopBP1 binding abolishes that asymmetry, snapping the dimer into a near-symmetric conformation that promotes ATR–ATRIP autophosphorylation and drives efficient phosphorylation of Chk1. Detailed atomic contacts reveal how this is achieved: an intensive network of hydrogen bonds welds a TopBP1 beta strand to the M-HEAT domain, the tryptophan residue W1145 of TopBP1 buries into a hydrophobic pocket at the N-HEAT/M-HEAT junction, and salt-bridge interactions fasten a TopBP1 helix onto the N-HEAT superhelix.

Perhaps the most provocative observation concerns what happens after activation. The researchers purified ATR–ATRIP complexes that had been fully autophosphorylated in the presence of TopBP1, then stripped the activator away and determined the structure of the phosphorylated kinase on its own. Remarkably, the phosphorylated complex remained fully competent to phosphorylate Chk1, and it did so regardless of how much TopBP1 was added back. Structurally, the released enzyme adopted an asymmetric conformation, yet its kinase domain was essentially indistinguishable from that of the TopBP1-bound, near-symmetric activated state. The authors conclude that catalytic activity is compatible with both near-symmetric and asymmetric architectures, meaning that phosphorylation — not a rigid, TopBP1-imposed symmetry — is the true durable switch. Once ATR has phosphorylated itself, the checkpoint engine keeps running even if its ignition key is removed, a property with clear implications for how sustained checkpoint signaling is maintained at damaged replication forks.

The autophosphorylation story was reinforced biochemically. Mass spectrometry mapped dozens of newly phosphorylated sites on ATR and ATRIP, and phosphatase treatment confirmed that the mobility shifts seen in gels were genuinely phosphorylation-dependent. Activity assays showed a clean dose-response: non-phosphorylated ATR–ATRIP phosphorylated Chk1 only when TopBP1 was titrated in, whereas the pre-phosphorylated complex catalyzed Chk1 modification at TopBP1 concentrations approaching zero. Interestingly, an isolated ATR head domain displayed only basal activity with or without TopBP1, underscoring that the full dimeric scaffold — and its TopBP1-driven reorganization — is required to reach full catalytic power. Together these experiments elevate ATR autophosphorylation from a correlative biomarker to a mechanistically demonstrated molecular switch for checkpoint activation.

The paper’s second act concerns therapy. ATR inhibitors such as berzosertib (VX-970/M6620), ceralasertib (AZD6738), gartisertib (VX-803/M4344) and elimusertib (BAY 1895344) are in clinical development as sensitizers that push tumor cells with pre-existing DNA repair defects over the edge. The team determined four separate inhibitor-bound structures of ATR–ATRIP, one for each compound, providing the first side-by-side atomic views of how this pharmacological class occupies the ATR active site. The nucleotide-binding pocket turns out to be divisible into four sub-compartments: an adenine-binding pocket lined by residues including M2325, Y2365, I2377, W2379 and V2380; an inner hydrophobic pocket; a ribose-binding site; and a triphosphate-binding site. All four inhibitors anchor themselves in the adenine pocket, but each then exploits the pocket’s flexibility differently, extending flanking chemical groups into the hydrophobic cavity, the ribose site, or the triphosphate region.

These structures explain both potency and selectivity. ATR’s adenine and hydrophobic sub-pockets are shifted toward the C-lobe relative to the corresponding sites in DNA-PKcs, mTOR and ATM, a displacement caused by the bulky side chains of M2325 and V2493 in ATR. Inhibitors can therefore nestle into an ATR-specific geometry that the closely related PIKK kinases cannot accommodate. Superimposition with structures of DNA-PKcs, mTOR and ATM further showed that a key hydrogen bond formed by berzosertib with glycine 2385 of ATR would be sterically blocked by the larger residues occupying the equivalent positions in the sibling kinases. In effect, the drugs exploit the conformational plasticity of the ATR active site — the very same flexibility that allows ATPγS to prime the kinase — to achieve multipocket engagement that favors ATR over its family members. For medicinal chemists, the four structures amount to a comparative map of which sub-pockets each clinical candidate touches, a starting grid for designing next-generation inhibitors with improved selectivity and resistance profiles.

Taken together, the study delivers a structural framework in which ATR regulation can finally be read as a sequence of physically defined events. ATP binding primes the catalytic cleft and positions Chk1; TopBP1 binding to the HEAT scaffold reorganizes the dimer and licenses autophosphorylation; phosphorylation converts the enzyme into a durably active state that survives TopBP1 dissociation; and small molecules shut the whole system down by wedging into the plastic ATP pocket. The work also resonates with parallel findings on ATM, where asymmetric activation of the dimeric kinase has recently been visualized, hinting at shared regulatory logic across the PIKK family. For cancer biology, the implications are tangible: tumors rely obsessively on ATR to survive their own replication chaos, and a structure-level understanding of both the activation switch and the drug-binding pocket should accelerate the design of inhibitors that hit ATR harder and more selectively. As ATR inhibitors advance through clinical trials, the molecular movie assembled by Wang, Cheng, Qiao and colleagues provides the kind of mechanistic blueprint on which the next generation of checkpoint-targeted therapies can be drawn.

Subject of Research: Cryo-EM structural mechanisms of phosphorylation-driven activation and inhibitor binding of the human ATR–ATRIP checkpoint kinase complex

Article Title: Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR–ATRIP

Article References: Wang, L., Wang, M., Zhao, L., Rao, Q., Wu, H., Ma, B., Wang, J., Zheng, J., Li, Y., Xu, Y., Guo, J., Cheng, J., & Qiao, S. (2026). Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR–ATRIP. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01887-4

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01887-4

Keywords: ATR, ATRIP, TopBP1, Chk1, cryo-electron microscopy, DNA damage response, replication stress, autophosphorylation, kinase activation, ATR inhibitors, berzosertib, cancer therapy

During the vital process of DNA replication, the replication forks act as molecular engines by unwinding the DNA double helix and facilitating the synthesis of new strands. However, these forks can encounter obstacles such as DNA damage, replication stress, or chemotherapeutic agents, which risk fork stalling or collapse. To mitigate such detrimental events, cells deploy a protective mechanism wherein the forks reverse to form a unique four-way junction structure. This reversal not only temporarily stalls replication to allow for damage tolerance but also acts as a safeguard against the formation of lethal DNA double-strand breaks.

Despite the recognition of reversed replication forks as central players in maintaining genomic integrity, their study has been hampered by a lack of tools able to visualize these transient structures in situ with high specificity and resolution. Traditional approaches have relied heavily on in vitro assays or bulk analyses, obscuring the intricate spatial and temporal context these structures inhabit within native chromatin. The RF-SIRF imaging technology fills this critical gap by enabling the single-cell resolution mapping of reversed forks within their native cellular environment, providing a window into the molecular choreography at stalled replication sites.

The technical foundation of RF-SIRF capitalizes on the distinct four-way architecture of reversed forks, employing a combination of immunofluorescent labeling and proximity ligation techniques to detect and quantify these unique DNA junctions. This method allows for the spatial correlation of reversed forks with a myriad of chromatin features and DNA repair proteins, thereby unraveling the complex interplay between DNA replication stress responses and epigenetic regulation in living cells. As a consequence, the approach unveils a rich “epigenetic code” tied explicitly to replication stress that markedly diverges from the regulatory landscapes governing canonical gene transcription.

This epigenetic signature, identified through RF-SIRF, illuminates how stalled forks actively recruit specific DNA damage response factors. Such localization not only influences repair pathway choice but also intertwines with inflammatory and transcriptional programs, potentially mediating cancer resistance and aging phenotypes. These insights mark a paradigm shift by revealing that reversed forks are not merely passive structures halting replication but are dynamically embedded in signaling circuits that influence cell fate decisions.

In the context of oncology, this discovery holds transformative implications. Many cancers, especially those harboring mutations in BRCA1 and BRCA2—genes critical for fork protection—exemplify altered responses to replication stress, influencing their sensitivity to chemotherapy and immunotherapy. By delineating the molecular underpinnings of fork reversal in these contexts, RF-SIRF sets the stage for precision medicine strategies designed to target therapy resistance mechanisms at their molecular inception. This tool empowers researchers to visualize hidden resistance pathways and test novel therapeutic interventions directly at the single-cell level.

Katharina Schlacher, Ph.D., the leading investigator of this study, emphasizes that the ability to decode the “crosstalk” between DNA replication stress, inflammation, and transcription unfolds new frontiers in precision oncology. “Our imaging platform doesn’t just reveal where and when forks reverse; it exposes the epigenetic signals orchestrating the cellular response to replication stress, unveiling possible targets to circumvent cancer’s adaptive resistance,” Schlacher notes.

From a broader perspective, RF-SIRF opens avenues to investigate how replication stress responses influence aging and disease suppression. Alterations in fork dynamics and associated epigenetic landscapes may underpin age-related genomic instability and immunotherapy outcomes, expanding the relevance of this research beyond oncology into fundamental biology and translational medicine.

Moreover, by providing a quantitative, native context visualization, RF-SIRF empowers future studies to dissect how external stressors, including environmental factors and pharmacological agents, modulate replication fork behavior. This capacity promises to enhance our understanding of gene-environment interactions at the molecular level, contributing to more effective therapeutic designs that minimize collateral genomic damage.

This breakthrough exemplifies how integrating cutting-edge imaging technologies with molecular biology can decode complex cellular mechanisms that were previously obscured. The investigative team’s collaborative efforts, supported by the National Institute of Environmental Health Sciences and the Cancer Prevention and Research Institute of Texas, underscore the critical role of interdisciplinary research in advancing biomedical science.

The detailed findings are published in the prestigious journal Nature Communications, where they outline the mechanistic insights and potential clinical applications of RF-SIRF. This study not only marks a significant leap in DNA replication research but also offers a promising new tool for dismantling the molecular basis of cancer resistance and optimizing therapeutic responses.

As cancer treatment paradigms increasingly shift toward tailored and combination therapies, tools like RF-SIRF stand to revolutionize the early detection of resistance mechanisms and pave the way for more intentional and effective interventions. By shining light on the spatial and temporal dimensions of replication fork dynamics, this technology sets a new standard for molecular oncology research and personalized medicine.

The advent of RF-SIRF heralds a future where the intricate dance of DNA replication and repair can be charted with the clarity needed to design next-generation therapies that will ultimately improve patient outcomes and longevity.

Subject of Research: DNA replication fork reversal dynamics and epigenetic regulation in cancer biology

Article Title: Novel RF-SIRF Imaging Tool Decodes Reversed DNA Replication Forks with Single-Cell Resolution, Unveiling Cancer Therapy Resistance Mechanisms

News Publication Date: April 27, 2026

Web References:
https://www.mdanderson.org/
https://www.nature.com/articles/s41467-026-70716-5

References: Published study in Nature Communications by Katharina Schlacher et al.

Keywords: DNA replication, reversed replication forks, genomic stability, replication stress, epigenetic signaling, cancer resistance, BRCA mutations, chemotherapy, immunotherapy, precision oncology, RF-SIRF imaging, DNA damage response

Replication forks are dynamic DNA structures arising during genome duplication where the DNA double helix unwinds, allowing enzymatic machinery to faithfully copy genetic information. However, when replication encounters obstacles such as endogenous lesions or replication stress, the replication fork can stall or collapse, resulting in single-ended double-strand breaks that pose a significant threat to genomic integrity. Traditionally, the cell was thought to predominantly employ BIR to mend such damage. BIR leverages an intact homologous DNA template to restart replication, thereby preserving genetic fidelity but operating at a relatively slow pace.

Contrasting with BIR, MMEJ is a more rapid, though error-prone, repair mechanism that aligns short homologous DNA sequences—microhomologies—to join broken DNA ends. Historically, MMEJ has been considered a backup mechanism, primarily mediating repair of double-ended breaks independent of replication. This new research overturns that paradigm by revealing that MMEJ, catalyzed by Polθ, is directly engaged at broken replication forks. Employing CRISPR nickase technology to precisely induce replication fork collapse and using sophisticated reporter systems alongside genome sequencing, the researchers identified unique mutational footprints inconsistent with canonical BIR but characteristic of fork-specific MMEJ.

These observations suggest that the MMEJ operating at replication forks—termed fork-MMEJ—differs mechanistically and functionally from its standard counterpart. Unlike canonical MMEJ, fork-MMEJ is initiated by the replication protein A (RPA), a single-stranded DNA-binding protein active during replication stress. This initiation results in asymmetric deletion patterns flanking the break site, creating a distinctive mutational signature frequently observed in various cancer genomes. Such error-prone repair may offer a double-edged sword: while compromising genome stability, it paradoxically confers tumors with resilience against lethal DNA damage, enabling continued proliferation under stress conditions.

Polθ’s central role in this process positions it as an even more compelling target for anticancer drug development than previously appreciated. Notably, tumors deficient in homologous recombination repair pathways, including those harboring BRCA1 or BRCA2 mutations, are especially reliant on Polθ-mediated MMEJ for survival. Inhibiting Polθ in these contexts disrupts the tumor cells’ ability to cope with replication-associated damage, selectively undermining their viability.

In a novel therapeutic insight, the study also highlights the interplay between fork-MMEJ and BIR regulated by the ATR kinase—a protein that senses DNA damage and orchestrates repair pathway choice. ATR suppresses fork-MMEJ, favoring the more accurate but slower BIR. Intriguingly, simultaneous inhibition of ATR and Polθ amplifies cancer cell death under replication stress conditions, with minimal adverse effects on normal cells. This synergy opens promising avenues for combination therapies harnessing existing ATR inhibitors alongside emerging Polθ inhibitors, potentially overcoming resistance mechanisms and improving clinical outcomes.

The profound implication of this research lies in reframing the timing and hierarchy of DNA repair mechanisms at replication forks. Whereas MMEJ was thought to function predominantly downstream or in backup capacities, it now appears integral to initial responses against replication-induced DNA breakage. This understanding could transform strategic drug targeting, emphasizing the disruption of Polθ activity at the earliest stages of DNA damage repair.

Looking forward, the Scripps Research team is expanding their investigation to elucidate additional protein components within the fork-MMEJ pathway. Each newly identified factor may represent a novel molecular target, broadening the landscape for therapeutic intervention. Moreover, they seek to deepen insights into ATR’s modulatory role, deciphering the molecular switches that balance repair pathway engagement and influence cell fate under replication stress.

This paradigm-shifting discovery not only advances fundamental knowledge of DNA damage responses in cancer biology but also redefines potential treatment strategies. By illuminating how cancer cells co-opt an error-prone yet expedient repair mechanism at replication forks, it opens doors to innovative therapies aimed at exploiting this vulnerability. The work underscores the criticality of targeting replication stress responses, a hallmark of cancer, to selectively eliminate tumor cells while sparing normal tissues.

As therapies evolve to incorporate precision targeting of DNA repair enzymes, understanding the nuanced differentiation between repair pathways becomes essential. Polθ’s newfound prominence reinforces the urgency of completing clinical development of inhibitors that can effectively disrupt the MMEJ process at replication forks. Combined with ATR inhibition approaches, such treatments promise a new frontier in cancer therapy, characterized by enhanced specificity and fewer side effects.

In summary, this compelling study marks a transformative advance in the field of cancer genomics and DNA repair. It challenges long-standing dogma, unveiling a previously underappreciated mechanism of fork-associated DNA repair mediated by Pol theta and MMEJ. This deeper mechanistic insight not only elucidates how tumors endure relentless replication stress but also provides a robust foundation for next-generation therapeutic strategies aimed at crippling cancer cells’ adaptive DNA repair capabilities.

Subject of Research: DNA repair mechanisms operative at broken replication forks in cancer cells, focusing on Pol theta–mediated microhomology-mediated end joining.

Article Title: Microhomology-mediated end joining acts directly on replication forks to repair single-ended double-strand breaks.

News Publication Date: 16-Mar-2026

Web References:
https://www.cell.com/molecular-cell/fulltext/S1097-2765(26)00130-9
http://dx.doi.org/10.1016/j.molcel.2026.02.016

References:
Li, S., Zhao, Y., Li, Y., Shah, S.B., Shi, Y., Nguyen, T., Bu, T-H., Loguercio, S., Sussman, J.H., Wang, Z., Chang, C-Y., Aladjem, M.I., Ray, A., Sasaki, T., Gilbert, D.M., Wang, H., Wu, X. (2026). Microhomology-mediated end joining acts directly on replication forks to repair single-ended double-strand breaks. Molecular Cell.

Image Credits: Scripps Research

Keywords: DNA damage response, replication fork collapse, Pol theta, microhomology-mediated end joining, break-induced replication, replication stress, DNA repair pathways, cancer therapeutics, ATR kinase, BRCA mutations, genome stability, replication-associated DNA breaks